BI 3031185 in Borderline Personality Disorder or ADHD

Phase 1, randomised, double-blind trial of BI 3031185 in borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of participants with borderline personality disorder (BPD) reporting adverse events (AEs) deemed by the investigator to be related to the investigational medicinal product (IMP) at 28 days and Number of participants with attention deficit/hyperactivity disorder (ADHD) reporting AEs deemed by the investigator to be related to the IMP at 28 days. Started Aug 2025; status: completed.